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Abstract
Objective: Comparison of prospectively treated patients with neoadjuvant cisplatin-based chemotherapy vs radiochemotherapy followed by
resection for mediastinoscopically proven stage III N2 non-small cell lung cancer with respect to postoperative morbidity, pathological nodal
downstaging, overall and disease-free survival, and site of recurrence. Methods: Eighty-two patients were enrolled between January 1994 to
June 2003, 36 had cisplatin and doxetacel-based chemotherapy (group I) and 46 cisplatin-based radiochemotherapy up to 44 Gy (group II), either
as sequential (25 patients) or concomitant (21 patients) treatment. All patients had evaluation of absence of distant metastases by bone
scintigraphy, thoracoabdominal CT scan or PET scan, and brain MRI, and all underwent pre-induction mediastinoscopy, resection and
mediastinal lymph node dissection by the same surgeon. Results: Group I and II comprised T1/2 tumors in 47 and 28%, T3 tumors in 45 and 41%,
and T4 tumors in 8 and 31% of the patients, respectively (PZ0.03). There was a similar distribution of the extent of resection (lobectomy, sleeve
lobectomy, left and right pneumonectomy) in both groups (PZ0.9). Group I and II revealed a postoperative 90-d mortality of 3 and 4% (PZ0.6), a
R0-resection rate of 92 and 94% (PZ0.9), and a pathological mediastinal downstaging in 61 and 78% of the patients (P!0.01), respectively.
5y-overall survival and disease-free survival of all patients were 40 and 36%, respectively, without significant difference between T1–3 and T4
tumors. There was no significant difference in overall survival rate in either induction regimens, however, radiochemotherapy was associated
with a longer disease-free survival than chemotherapy (PZ0.04). There was no significant difference between concurrent vs sequential
radiochemotherapy with respect to postoperative morbidity, resectability, pathological nodal downstaging, survival and disease-free survival.
Conclusions: Neoadjuvant cisplatin-based radiochemotherapy was associated with a similar postoperative mortality, an increased pathological
nodal downstaging and a better disease-free survival as compared to cisplatin doxetacel-based chemotherapy in patients with stage III (N2)
NSCLC although a higher number of T4 tumors were admitted to radiochemotherapy.
Q 2005 Elsevier B.V. All rights reserved.
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Induction chemotherapy followed by resection has been
shown to improve the survival in patients with stage IIIA (N2)
non-small cell lung cancer (NSCLC) as compared to resection
alone in three out of four phase III trials [1–4]. The expected
outcome of induction chemotherapy followed by resection
in locally advanced but still resectable NSCLC shows1010-7940/$ - see front matter Q 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejcts.2005.02.035
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nodes, downstaging and an improved chance for complete
resection, as well as early eradication of micrometastases
[5]. However, the ideal induction regimen with optimal
control of disease and minimal associated morbidity has not
yet been defined since the complete pathological response
rate after induction therapy is actually around 5–10%.
The results emerging from neoadjuvant chemotherapy
followed by resection suggest that post-resectional survival
is strongly related to the degree of pathological downstaging
achieved by the induction regimen and that mediastinal
downstaging seems to be a particularly important prognostic
predictor in this respect [6–9]. However, neoadjuvant
chemotherapy alone, even with cisplatin-doxetacel-based
regimens affords a pathologic complete response of approxi-
mately 15% indicating that local control with currentlyEuropean Journal of Cardio-thoracic Surgery 27 (2005) 1092–1098www.elsevier.com/locate/ejcts
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impression is reinforced by the findings of another prospec-
tive study which has assessed the pattern of recurrence after
neoadjuvant MVP-based chemotherapy followed by resec-
tion [10]. Both studies have found a similar pattern of
recurrence with a high rate of local recurrence. These
findings suggest that the consideration of radiotherapy in
combination with chemotherapy in the context of neoadju-
vant treatment of locally advanced, resectable NSCLC may
be worthwhile. Several studies have demonstrated the
feasibility of neoadjuvant radiochemotherapy followed by
resection in this setting and have shown better survival rates
as compared with historical results [8,11–15]. This holds
especially true for superior sulcus tumors [14,15]. However,
there is lack of reports comparing neoadjuvant cisplatin-
based radiochemotherapy with cisplatin-based chemother-
apy for locally advanced, resectable NSCLC in a standardized
setting. Furthermore, the impact of concurrent or sequen-
tial administration of irradiation and chemotherapy has not
been assessed in this respect.
In this observational study, we compared two non-
randomized groups of patients with stage III (N2) NSCLC
receiving either neoadjuvant cisplatin-based chemotherapy
or cisplatin-based radiochemotherapy followed by resection
with respect to resectability, postoperative morbidity,
pathological nodal downstaging, survival, disease-free sur-
vival (DFS) and pattern of recurrence.2. Patients and methods
2.1. Patient selection
The studied population consisted of all patients with
stage III N2 NSCLC who underwent neoadjuvant cisplatin-
based chemotherapy or radiochemotherapy and subsequent
resection by the same thoracic surgeon (HBR) between
January 1994 and June 2003. Patients were evaluated in an
interdisciplinary setting and investigated, treated and
followed in a prospective manner. The treatment protocols
were approved by the local Ethical Committee and informed
consent was obtained.
Inclusion criteria were age !75 years, Karnofsky per-
formance status of O80%, a creatinine clearance of
O60 ml/min, cardiopulmonary functions allowing complete
resection and mediastinoscopically proven stage III N2 NSCLC
without progression after induction therapy as assessed by
CT-scan. Selected and potentially resectable T4 tumors with
partial involvement of the carina, the vena cava superior or
the left recurrent nerve were included. Exclusion of distant
metastases was performed by CT scan of the chest and
abdomen, bone scan or PET scan, and brain MRI or CT in all
patients. Mediastinoscopy was always performed by the
same surgeon (HBR) and included biopsy of lymph nodes ATS
7, and 4 and 2 on both sides. Patients with NSCLC of the left
upper lobe with enlarged or positive ATS 5 or 6 nodes on CT
or PET scan, respectively, plus negative mediastinoscopy
underwent thoracoscopic exploration and biopsy of these
nodes. Patients with tumor involvement of ATS 5 and 6 nodes
were included. Patients with mediastinoscopically proven
N3 disease, a malignant pleural or pericardial effusion, T4tumors with invasion of the esophagus and the aorta or
intrapericardial tumor extension were excluded, as well as
patients with progressing disease after induction therapy.
Induction therapy consisted of a cisplatin-based che-
motherapy in all patients. Preoperative induction treat-
ment allocation was not random, but based on availability
of multicenter protocols on neoadjuvant chemotherapy and
choice of the referring oncologist. Patients with IIIA
disease were considered for neoadjuvant chemotherapy
alone or neoadjuvant chemoradiotherapy depending on
the year of treatment. Patients with superior sulcus
tumors and IIIB disease were to receive neoadjuvant
chemoradiotherapy.
In group I (chemotherapy), patients received three cycles
of cisplatin (100 mg/m2) and doxetacel (85 mg/m2) on day 1,
22 and 43. In group II (radiochemotherapy), patients were
treated either with three cycles of cisplatin-based che-
motherapy (cisplatin 100 mg/m2, doxetacel 85 mg/m2 on
day 1, 22 and 43) followed by accelerated radiotherapy up to
44 Gy, or with three cycles of cisplatin-based chemotherapy
(cisplatin 60 mg/m2, vinblastine 6 mg/m2 on day 1, 22 and
43) and concomitant hyperfractionated accelerated radio-
therapy with 2!1.6 Gy/d for 5 days during each cycle of
chemotherapy. All patients were treated with megavoltage
photon beams O10 MV after three-dimensional treatment
planning. The planning target volume included the primary
tumor, the ipsilateral hilum and the mediastinum. The
resection was performed within 3 weeks after the end of
induction therapy.
Resection consisted of complete en bloc removal of the
involved lobe(s) or lung together with involved adjacent
structures (chest wall, pericardium, subclavian vessels, SVC,
part of the carina) according to the extent of the disease
found at surgery. Frozen section examination of the
bronchial resection margin was routinely performed. Recon-
struction of the SVC or subclavian vessels was performed
with PTFE grafts, the pulmonary artery with pericardial
patch angioplasty and chest wall defects by use of
mersilene-methylmethacrylate substitutes if required.
Bronchoplastic procedures (sleeve lobectomy) were used in
order to avoid pneumonectomy if appropriate. Tension-free
end-to-end anastomoses were performed by use of inter-
rupted sutures and wrapped by an intercostal muscle flap. An
intrapericardial hilar release was performed if required.
Centrally located tumors involving the proximal main stem
bronchus and the carina were treated preferentially by a
carinal wedge resection with re-implantation of remnant
lobe(s) within the carinal defect, or closure of the carinal
defect by a latissimus dorsi muscle flap in case of
pneumonectomy, in order to avoid carinal pneumonectomy.
Bronchial stump coverage was always performed, either by
use of an intercostal muscle flap after lobectomy or
pneumonectomy without thoracic irradiation, or a latissimus
dorsi or diaphragmatic flap after intrapericardial pneumo-
nectomy or pneumonectomy following thoracic irradiation
[16,17]. Formal mediastinal lymph node dissection was
performed in every patient according to Martini et al. [18].
Division of the azygous vein on the right side and if required
of the Botalli ligament on the left side, respectively, were
performed in order to achieve appropriate para-and pre-
tracheal lymph node dissection.
Table 1
Characteristics of 82 patients undergoing neoadjuvant cisplatin-based
chemotherapy or radiochemotherapy and subsequent resection for stage III
N2 NSCLC
Chemother-
apy (nZ36)
Radio-chemo-
therapy (nZ46)
P-value
Age (meanGSD) 60 (G9) 57 (G10) 0.17
Gender
Male 25 (69%) 37 (80%) 0.25
Female 11 (31%) 9 (20%)
Tumor stage
T1/T2 17 (47%) 13 (28%) 0.03
T3 16 (45%) 19 (41%)
T4 3 (8%) 14 (31%)
Histology
Squamous cell 17 (47%) 20 (43%) 0.08
Adeno 8 (22%) 10 (22%)
Large cell 7 (20%) 16 (35%)
Poorly differentiated 4 (11%) 0
N2 status
Single station 21 (58%) 20 (43%) 0.26
Bulky/multilevel 15 (42%) 26 (57%)
Resection
Right pneumonectomy 9 (25%) 10 (22%) 0.93
Left pneumonectomy 6 (17%) 9 (19%)
Lobectomy, bilobectomy 19 (53%) 23 (50%)
Sleeve lobectomy 2 (5%) 4 (9%)
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performed on the primary tumor and all lymph nodes in order
to determine the pathological downstaging after induction
therapy. All tissue samples were fixed in 4% buffered
formalin, embedded in paraffin and 4m-thick sections were
stained with H&E. Histological slides of all tumors were
reviewed by trained pulmonary pathologists who had no
knowledge of the given induction regimen. Intrapulmonary,
peribronchial, hilar and mediastinal lymph nodes were
carefully evaluated for metastatic deposits. The tumors
were classified using the stage grouping system of the 2002
TNM classification of malignant tumors meaning that pN0
corresponds to tumor-free nodes, pN1 to metastases in
ipsilateral intrapulmonary, peribronchial or hilar nodes, and
pN2 to metastases in ipsilateral mediastinal or subcarinal
nodes. Immunohistochemistry was used for tumor recog-
nition, if required.
Postoperative morbidity and mortality and life-threaten-
ing complications were recorded and analyzed up to 90 days
after the operation in all patients.
2.2. Follow-up
Patients underwent physical examination, blood chem-
istry and a chest X-ray every 3 months up to 2 years, every 6
months from 2 to 5 years, and then annually after the
resection. A CT-scan of the chest and upper abdomen was
performed every 6 months within 2 years after resection and
then annually thereafter. Survival and disease-free survival
were calculated from the day of surgery until death of the
patient or manifestation of tumor recurrence, respectively.
2.3. Statistical analysis
The Chi2 and Fisher’s exact test were used to determine
differences inproportionswhereappropriate.The log rank test
was used to compare Kaplan-Meier curves (overall and DFS).
Multivariate Cox regression analysis was performed to com-
pare overall survival and DFS according to the treatment
performed and adjusted for age, gender and T-stage (T1–3 vs
T4). Likewise, the prognostic value of pathological nodal
downstaging was also evaluated. Proportionality assumption
was tested and the appropriate functional form for continuous
co-variables was assessed using fractional polynomials. P
values !0.05 were considered significant. Interactions were
not assessed because of the small number of events and risk of
overfitting. All analyses were carried out using STATA, version
8 (Stat Corp, College Station, TX, USA).3. Results
Eighty-two patients underwent induction therapy fol-
lowed by resection for stage III N2 NSCLC, 36 with cisplatin-
doxetacel based chemotherapy (group I), and 46 with
cisplatin-based radiochemotherapy (group II). Twenty-five
patients underwent sequential and 21 concomitant radio-
chemotherapy. The patient characteristics of the studied
population are shown in Table 1. There were 62 men and 20
women with a mean age of 58.5 years (range 35–74 years)without significant differences between the groups. Squa-
mous cell carcinoma was found in group I and II in 47 and
43%, adenocarcinoma in 22 and 22%, large cell carcinoma in
20 and 35%, and poorly differentiated carcinoma in 11% and 0
of the patients, respectively (PZ0.08). Single station N2
disease was found in group I and II in 58 and 43%, and bulky/
multilevel N2 disease in 42 and 57% of the patients,
respectively (PZ0.26). Group I and II comprised T1/2 tumors
in 47 and 28%, T3 tumors in 45 and 41%, and T4 tumors in 8
and 31% of the patients, respectively. T4 tumors were more
frequently pretreated with radiochemotherapy than chemo-
therapy (PZ0.03). There was no significant difference in the
extent of resection (lobectomy, sleeve lobectomy, left and
right pneumonectomy) in either groups (Table 1). After
neoadjuvant chemotherapy and radiochemotherapy, carinal
wedge resections were performed in 8 and 9%, reconstruc-
tions of the pulmonary artery, subclavian artery and superior
vena cava in 3 and 7%, and chest wall resections in 3 and 24%
of the patients, respectively.
Complete resection after chemotherapy and radioche-
motherapy was achieved in 92 and 94%, a R1-resection in 6
and 4%, and a R2-resection in 3 and 3% of the patients,
respectively (PZ0.9), (Table 2). Tumor-free bronchial
resection margins were found in 81/82 patients, and in all
patients with sleeve lobectomy and carinal wedge resection.
One of 12 patients with chest wall resection had incomplete
resection at the level of the chest wall. All patients
undergoing vessel resection and reconstruction (SVC, sub-
clavian vessels, pulmonary artery) had complete resections.3.1. Postoperative mortality and life-threatening
complications
The 90d-mortality rate was 3 and 4% after chemother-
apy and radiochemotherapy, respectively (PZ0.6). After
Table 2
Secondary outcomes of 82 patients undergoing neoadjuvant cisplatin-based
chemotherapy or radiochemotherapy and subsequent resection for stage III N2
NSCLC
Chemotherapy
(nZ36)
Radio-chemo-
therapy (nZ46)
P-value
Completeness of resection
R0 33 (92%) 43 (94%) 0.95
R1 2 (6%) 2 (4%)
R2 1 (3%) 1 (2%)
Pathological nodal downstaging
pN0 12 (33%) 31 (67%) !0.01
pN1 10 (28%) 5 (11%)
pN2 14 (39%) 10 (22%)
90d-postoperative mortality and morbidity
Mortality 1 (3%) 2 (4%) 0.64
Pneumonia 1 (3%) 3 (6%) 0.63
ARDS 1 (3%) 7 (13%) 0.09
Pulmonary
embolism
1 (3%) 1 (2%) 0.86
Bronchopleural
fistula
2 (5%) 2 (4%) 0.81
0.00
0.25
0.50
0.75
1.00
0 12 24 36 48 60 months
Chemotherapy Radiochemotherapy
Survival
0.00
0.25
0.50
0.75
1.00
0 12 24 36 48 60 months
Chemotherapy Radiochemotherapy
DFS
(a)
(b)
Fig. 1. (a) Overall survival and (b) disease free survival in 82 patients
undergoing neoadjuvant cisplatin-based chemotherapy or radiochemotherapy
and subsequent resection for stage III N2 NSCLC.
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lism 40 days after pneumonectomy. After radiochemother-
apy, two patients died from ARDS 30 days after lobectomy
and chest wall resection, and 70 days after sleeve
bilobectomy, respectively. The incidence of postoperative
complications was not significantly different after che-
motherapy or radiochemotherapy for pneumonia (3 vs
6%), pulmonary embolism (3 vs 2%) and bronchopleural
fistula (5 vs 4%). However, the incidence of postoperative
ARDS was higher after radiochemotherapy (13%) than after
chemotherapy (3%), (PZ0.09). Anastomotic dehiscence or
bronchopleural fistulas were not observed after sleeve
resections, however, one patient developed stenosis at
the level of the anastomosis after sleeve bilobectomy
with poststenotic abscess formation and died from ARDS
70 days after operation (Table 2).3.2. Pathological nodal downstaging
After chemotherapy, histological examination of the
surgical specimen revealed pN0 in 33% and mediastinal
downstaging (pN0/pN1) in 61% of the patients. After
radiochemotherapy, pN0 was observed in 67% and media-
stinal downstaging (pN0/pN1) in 78% of the patients. The
difference in pathological nodal downstaging between
chemotherapy and radiotherapy was significant (P!
0.01). There was no significant difference between
concomitant and sequential radiochemotherapy with
respect to pN0 (76 vs 60%) and pN0/pN1 (76 vs 80%)
downstaging (Table 2).
The median follow up time was 53 months with an
interquartile range of 15.6–111.3 months.
Overall 5y survival of all patients was 40% without
significant difference between T1–3 and T4 tumors. The
overall survival was not significantly different between
chemotherapy and radiochemotherapy (Fig. 1a), nor
between concomitant and sequential radiochemotherapy.
Pathological nodal downstaging had a significant impact on
overall survival (P!0.01). Multivariate analysis adjusted
for age, gender and T-stage revealed pathological nodaldownstaging as the only significant predictor for overall
survival (Table 3).
Disease-free 5y-survival was 36% for all patients with-
out significant difference between T1–3 and T4 tumors.
The DFS was significantly better after radiochemotherapy
as compared to chemotherapy (PZ0.04), (Fig. 1b). There
was no significant difference between concurrent and
sequential radiochemotherapy in DFS. Pathological nodal
downstaging had a significant impact on DFS (PZ0.04).
Multivariate analysis adjusted for age, gender and T-stage
revealed that radiochemotherapy and the absence of
persistent mediastinal N2 disease after induction therapy
were both associated with a significantly better DFS
(Table 3).3.3. Site of recurrence
After neoadjuvant chemotherapy and resection, 33% of
the patients were tumor-free during follow-up, 23%
developed local recurrence and 44% distant metastasis.
After neoadjuvant radiochemotherapy and resection, 65%
of the patients were tumor-free during follow-up, 9%
developed local recurrence and 26% distant metastases.
Table 3
Multivariate analysis of the association between selected factors (induction
regimen and pathological nodal downstaging), and survival and DFS in 82
patients undergoing neoadjuvant cisplatin-based chemotherapy or radio-
chemotherapy and subsequent resection for stage III N2 NSCLC
Hazard ratio 95% CI P-value
Survival
Treatment 0.38
Chemotherapy 1 – –
Radiochemotherapy 0.73 [0.36–1.48] 0.38
Pathological nodal downstaging !0.01
pN0 1 – –
pN1 2.75 [1.08–6.97] 0.03
pN2 3.19 [1.47–6.90] !0.01
Disease free survival (DFS)
Treatment 0.04
Chemotherapy 1 – –
Radiochemotherapy 0.52 [0.26–1.01] 0.04
Pathological nodal downstaging 0.04
pN0 1 – –
pN1 1.59 [0.62–4.08] 0.33
pN2 2.37 [1.18–4.77] 0.02
All analyses are adjusted for age, gender and T-stage (T1–3 vs T4).
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and sequential radiochemotherapy in this respect.4. Comment
Lung cancer remains a widespread malignancy and even
modest improvements of treatment are potentially ben-
eficial to large numbers of patients. Locally advanced
disease without distant metastases is frequently present at
diagnosis but survival remains disappointingly low even after
complete resection in potentially operable patients. Induc-
tion therapy followed by resection has been investigated for
potentially resectable stage III NSCLC in order to improve the
outcome in these patients. Four prospective randomized
trials compared preoperative chemotherapy and surgery
with surgery alone and three of them demonstrated a
survival advantage after induction chemotherapy [1–4].
Although these three studies [1–3] were criticized for their
small sample size, imbalance between groups and poorer-
than-expected outcomes in the control groups, it is actually
believed that otherwise healthy patients with locally
advanced (N2) disease should receive neoadjuvant che-
motherapy and subsequent resection in case of response [5].
A number of studies have identified pathologic down-
staging after induction therapy as an important prognostic
factor which should be taken into consideration for
validation of a particular induction regimen [6–9]. The
currently used neoadjuvant chemotherapy regimens have
shown a disappointingly low complete pathological response
rate. Martini et al. found a sterilization rate of 14% after 3
cycles of MVP, and Betticher et al. 15% after 3 cycles of
cisplatin/doxetacel induction therapy [6,10]. After neoad-
juvant chemotherapy, overall survival seems to be pro-
longed but local recurrences remain frequent. The two
studies have shown distant metastases in 23 and 19%, local
recurrence in 12 and 13.5%, and both, local and distantrelapse in 11 and 13.5% of the patients, respectively [6,10].
The total local failure rate was thus almost identical in both
studies (23 and 27%, respectively). These findings suggest
that the addition of radiotherapy may be worthwhile in order
to improve local control. Currently, patients with incom-
plete resection or tumor bearing mediastinal lymph nodes do
undergo postoperative adjuvant radiotherapy in many
institutions. Although the published results suggest a modest
decrease of local recurrence after adjuvant irradiation,
there is no evidence of overall survival benefit in these
situations [5].
Several phase II trials have demonstrated the feasibility
of induction radiochemotherapy followed by resection in
locally advanced NSCLC. Results emerging from combined
neoadjuvant radiochemotherapy and resection for Pancoast
or IIIB NSCLC have suggested a survival benefit as compared
to historical controls without induction therapy [5,11–15].
However, neoadjuvant radiochemotherapy has not been
compared to neoadjuvant chemotherapy alone for patients
with potentially resectable NSCLC in a standardized manner.
Furthermore, the optimal sequence of combined radio-
chemotherapy (concurrent vs sequential) has yet to be
determined. Results emerging from the treatment of non-
resectable NSCLC by radiochemotherapy suggest that con-
current therapy appears to be superior to sequential
treatment with respect to improvement of survival [5].
However, the concurrent approach appears to increase the
rate of adverse effects.
In this observational study, we compared two non-
randomized groups of patients with stage III (N2) NSCLC
receiving either neoadjuvant cisplatin-based chemotherapy
or cisplatin-based radiochemotherapy (sequential or con-
comitant) followed by resection with respect to resect-
ability, postoperative morbidity, pathological nodal
downstaging, survival, disease-free survival (DFS) and
pattern of recurrence. Preoperative induction treatment
allocation was not random, but based on availability of
multicenter protocols on neoadjuvant chemotherapy and
choice of the referring oncologist. Patients with superior
sulcus tumors and IIIB disease were to receive neoadjuvant
radiochemotherapy. Patient selection was stringent and
included only patients with resectable tumors without
progression on CT scan after induction therapy. All patients
had mediastinoscopically proven N2 disease [19]. Patients
with N3 nodal involvement or with distant metastases were
excluded. Patients with bulky and multilevel disease were
considered for induction therapy followed by resection if the
tumor appeared resectable at the time of enrollment. The
two groups were comparable with respect to age, gender,
tumor histology, N2 disease (single station vs bulky/multi-
level disease) and extent of resection. However, patients
with superior sulcus tumors and IIIB disease preferentially
received neoadjuvant chemoradiotherapy. Selected T4
tumors if they appeared resectable, such as tumors
infiltrating the lateral tracheo-bronchial angle, the left
recurrent nerve, and the SVC were also eligible. The
inclusion of selected patients with resectable T4 tumors in
neoadjuvant protocols seems justified since several reports
have demonstrated that their survival does not substantially
differ from that observed for T1–3N2 tumors after induction
therapy [11,13,20,21]. In fact, our results endorse these
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between T1–3 and T4 tumors in our series.
Complete R0-resection after chemotherapy and radio-
chemotherapy was achieved in 92 and 94%, respectively,
without difference between concomitant and sequential
radiochemotherapy. There was no difference between the
chemotherapy and radiochemotherapy group with respect to
R0-resections although there were more T4 tumors or tumors
with chest wall infiltration attributed to the radioche-
motherapy group. This confirms previous findings that
neoadjuvant radiochemotherapy offers a higher degree of
local downstaging in tumors with a propensity to invade
surrounding structures and where complete resection is
difficult to achieve due to anatomical considerations.
Several surgical maneuvers have been described to improve
complete resection after neoadjuvant therapy such as the
division of the azygous vein on the right and of the Botalli
ligament on the left side, and the liberal use of intraper-
icardial dissection and resection if required. Our results
endorse the previously reported finding that resection and
reconstruction of vascular and tracheo-bronchial structures
can be safely performed after induction therapy in order to
achieve a complete resection [20,21]. Centrally localized
tumors may be completely resected by a sleeve lobectomy
and carinal wedge resection followed by implantation of
the remnant lobe(s) into the carinal defect. This technique
avoids a hazardous carinal resection or sleeve pneumonect-
omy in pretreated tissues and has been performed in this
series on seven patients (three after chemotherapy and four
after radiochemotherapy) with a complete resection and
without anastomotic dehiscence in all patients. However,
one patient developed an anastomotic stenosis 70 days after
surgery with subsequent abscess formation, ARDS and death.
This was probably related to anastomotic tension despite a
hilar release having been performed. Carinal reconstruction
after a wedge pneumonectomy may also be performed by
use of an extrathoracic muscle flap transposed into the chest
cavity and sutured into the carinal defect in order to avoid
carinal pneumonectomy [22].
There was no significant difference in postoperative 90d-
mortality after neoadjuvant chemotherapy (3%) and radio-
chemotherapy (4%). The incidence of life-threatening
complications such as pulmonary embolism, pneumonia
and bronchopleural fistula was also not significantly different
between the two induction regimens. However, the inci-
dence of postoperative ARDS was higher after radioche-
motherapy (13%) than after chemotherapy (3%), which is in
accordance with other reports. Neoadjuvant radioche-
motherapy appears to increase the postoperative mortality
rate and morbidity as compared to neoadjuvant chemother-
apy alone, with mortality rates ranging between 0 and 18%
[8,11–15,23,24]. The incidence of postoperative ARDS in our
series was mainly observed after right pneumonectomy but
it also occurred after lobectomy following radiochemother-
apy. Careful postoperative monitoring of patients receiving
neoadjuvant radiochemotherapy for several days is manda-
tory in this respect and fluid overload should be avoided,
especially in patients with an impaired pulmonary function
and DLCO. Right-sided pneumonectomy after induction
therapy bears a postoperative mortality risk of 25% and
should be avoided whenever possible [25]. Bronchial stumpcoverage should be routinely performed in patients under-
going induction therapy and resection [16,17].
Pathological downstaging has been shown to be an
important predictor for survival for patients undergoing
neoadjuvant treatment following by resection for NSCLC and
nodal downstaging seems to be of particular importance in
this respect. Our results endorse these findings since
multivariate analysis of our data adjusted for age, gender
and T-status revealed pathological nodal downstaging as an
independent and significant predictor for overall survival and
DFS. Radiochemotherapy resulted in a significantly better
pathological nodal downstaging than chemotherapy in our
patients.
The 5y-overall and DFS of all patients was 40 and 36%,
respectively. There was no significant difference between
neoadjuvant radiochemotherapy and chemotherapy regard-
ing overall survival, however, radiochemotherapy resulted in
a significantly better DFS than chemotherapy alone. A
multivariate analysis of our data adjusted for age, gender
and T-status revealed that radiochemotherapy was associ-
ated with significantly better DFS. Patients with radio-
chemotherapy were at a significantly lower risk for recurrent
disease as compared to chemotherapy alone despite the fact
that more T4 tumors were attributed to the radioche-
motherapy group. These findings appear to be related to
the better capability of neoadjuvant radiochemotherapy for
pathological loco-regional downstaging as compared to
chemotherapy alone.
There was no significant difference between concomitant
vs sequential radiochemotherapy with respect to post-
operative morbidity, resectability, pathological nodal down-
staging, survival and DFS. However, caution in the
interpretation of these results is indicated due to the small
sample size.
In conclusion, our results emerging from an observational
non-randomised study suggest that neoadjuvant cisplatin-
based radiochemotherapy resulted in a similar postoperative
mortality, an increased pathological nodal downstaging, a
better DFS and a reduced risk for recurrence as compared to
cisplatin doxetacel-based chemotherapy in patients with
stage III N2 NSCLC although a higher number of T4 tumors
were admitted to radiochemotherapy. However, radioche-
motherapy was associated with a higher postoperative ARDS
rate than chemotherapy.References
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